| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21977e40c08969f3e950eb43ecafe0cb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5585 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5585 |
| filingDate |
2001-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a93ce243bc4c79fff97d28af65e3583 |
| publicationDate |
2002-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2002022644-A1 |
| titleOfInvention |
Treatment of ocular hypertension and glaucoma |
| abstract |
Disclosed is treatment of ocular hypertension and glaucoma by long-term therapy with a prostaglandin related compound for eliminating or reducing potential iridic pigmentation. Composition useful for the treatment, and use of the prostaglandin related compound for producing the composition are also disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009058493-A1 |
| priorityDate |
2000-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |